Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-549	PIK-93	2	72	sigmoid	sigmoid	BT549 PIK-93 0 2 72	8	1.983	7.03	0.687	0.0641	29.9	-1.0	0.759	0.956	8.81e-05	NA	10.4	0.713	0.939	10.4	0.0	0.788	0.949	0.000136	NA
HCC70	PIK-93	1	72	sigmoid	sigmoid	HCC70 PIK-93 0 1 72	8	1.442	3.47	0.482	0.137	18.6	-1.0	0.656	0.774	0.0116	NA	10.7	0.649	0.904	10.7	0.0	0.632	0.746	0.0163	NA
HCC70	PIK-93	2	72	sigmoid	sigmoid	HCC70 PIK-93 0 2 72	8	1.705	4.34	0.647	0.0132	9.3	-1.0	1.44	0.888	0.0014	NA	6.01	0.718	0.991	6.01	0.0	1.49	0.872	0.00208	NA
HCC70	PIK-93	3	72	sigmoid	sigmoid	HCC70 PIK-93 0 3 72	8	2.519	21.2	0.756	0.0663	181.0	-1.0	0.513	0.851	0.00333	NA	34.1	0.721	0.92	34.1	0.0	0.473	0.831	0.00487	NA
HCC38	PIK-93	3	72	sigmoid	sigmoid	HCC38 PIK-93 0 3 72	8	1.382	5.05	0.598	0.061	2.34	0.358	1.63	0.919	0.000533	NA	Inf	0.734	0.959	2.23	0.586	1.64	0.914	0.000645	NA
HCC38	PIK-93	2	72	sigmoid	sigmoid	HCC38 PIK-93 0 2 72	8	2.107	31.9	0.661	0.0151	2.16	0.497	1.86	0.922	0.000468	NA	Inf	0.676	0.987	1.97	0.545	1.87	0.907	0.000813	NA
HCC38	PIK-93	1	72	sigmoid	sigmoid	HCC38 PIK-93 0 1 72	8	1.741	5.24	0.61	0.0782	24.5	-1.0	0.713	0.982	6.07e-06	NA	9.93	0.686	0.935	9.93	0.0	0.729	0.979	9.08e-06	NA
BT-549	PIK-93	1	72	sigmoid	sigmoid	BT549 PIK-93 0 1 72	8	1.777	Inf	0.691	0.0438	1.77	0.561	1.47	0.989	1.31e-06	NA	Inf	0.742	0.963	1.64	0.646	1.47	0.988	1.83e-06	NA
BT-20	PIK-93	3	72	sigmoid	sigmoid	BT20 PIK-93 0 3 72	8	2.532	2.65	0.419	0.097	7.54	-1.0	1.05	0.982	5.47e-06	NA	2.5	0.42	0.892	2.5	0.0	1.17	0.971	2.45e-05	NA
HCC1806	PIK-93	3	72	sigmoid	sigmoid	HCC1806 PIK-93 0 3 72	8	3.206	56.0	0.873	0.0337	320.0	-0.872	0.579	0.859	0.00279	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC1806	PIK-93	2	72	sigmoid	sigmoid	HCC1806 PIK-93 0 2 72	8	2.838	41.1	0.857	0.038	265.0	-1.0	0.59	0.858	0.00286	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
BT-20	PIK-93	2	72	sigmoid	sigmoid	BT20 PIK-93 0 2 72	8	1.798	0.792	0.155	0.286	14.1	-1.0	0.382	0.81	0.00687	NA	2.8	0.373	0.764	2.8	0.0	0.344	0.77	0.0121	NA
HCC1806	PIK-93	1	72	sigmoid	sigmoid	HCC1806 PIK-93 0 1 72	8	2.753	44.0	0.853	0.0391	304.0	-1.0	0.568	0.858	0.00285	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.0	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.0	0.513	0.01	NA	NA	0.513
HCC70	Sirolimus	1	72	sigmoid	sigmoid	HCC70 rapamycin 0 1 72	8	1.416	37.6	0.533	0.397	0.00426	0.298	0.1	0.742	0.0172	NA	125000000.0	0.687	0.732	0.00186	0.541	0.1	0.74	0.0175	NA
HCC70	Sirolimus	2	72	flat	flat	HCC70 rapamycin 0 2 72	8	1.762	Inf	0.685	0.257	0.0	0.685	0.01	0.531	0.103	0.741	Inf	0.739	0.785	0.0	0.739	0.01	0.524	0.108	0.783
HCC70	Sirolimus	3	72	sigmoid	sigmoid	HCC70 rapamycin 0 3 72	8	2.548	310.0	0.732	0.227	0.000433	0.63	0.1	0.676	0.034	NA	22876.0	0.693	0.736	0.000237	0.58	0.1	0.659	0.0397	NA
BT-549	Sirolimus	3	72	flat	flat	BT549 rapamycin 0 3 72	8	1.703	Inf	0.455	0.482	0.0	0.455	0.01	0.376	0.243	0.518	Inf	0.582	0.626	0.0	0.582	0.01	0.436	0.179	0.625
BT-549	Sirolimus	2	72	flat	flat	BT549 rapamycin 0 2 72	8	1.830	Inf	0.569	0.384	0.0	0.569	0.01	0.517	0.113	0.618	Inf	0.642	0.677	0.0	0.642	0.01	0.465	0.153	0.679
BT-549	Sirolimus	1	72	sigmoid	sigmoid	BT549 rapamycin 0 1 72	8	1.817	3.62	0.51	0.438	0.000148	0.318	0.1	0.87	0.00218	NA	506850.0	0.6	0.638	8.82e-05	0.447	0.1	0.8	0.00802	NA
HCC1806	Sirolimus	1	72	sigmoid	sigmoid	HCC1806 rapamycin 0 1 72	8	2.796	1.35	0.775	0.187	0.00019	0.706	0.1	0.661	0.039	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA
HCC1806	Sirolimus	2	72	sigmoid	sigmoid	HCC1806 rapamycin 0 2 72	8	2.881	0.901	0.782	0.182	0.000189	0.714	0.1	0.661	0.0388	NA	149.0	0.717	0.76	0.000153	0.626	0.1	0.634	0.0489	NA
HCC1806	Sirolimus	3	72	sigmoid	sigmoid	HCC1806 rapamycin 0 3 72	8	3.249	0.223	0.805	0.162	0.000183	0.746	0.1	0.663	0.0382	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA
BT-20	Sirolimus	3	72	flat	flat	BT20 rapamycin 0 3 72	8	2.661	Inf	0.54	0.46	0.0	0.54	0.01	NA	NA	0.54	Inf	0.499	0.499	0.0	0.499	0.01	NA	NA	0.499
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.0	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.0	0.6	0.01	-13.0	1.0	0.6

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)